Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 3/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20377241 | 0.86 | PLA2G4A (0.54) | PLA2G4AFGFR1PLA2G4BTP53TSHR | |
| SCHEMBL1539111 | 0.80 | FGFR1 (0.53) | PLA2G4AFGFR1TP53TSHRSRC | |
| SCHEMBL11597463 | 0.78 | PLA2G4A (0.53) | PLA2G4AFGFR1 | |
| SCHEMBL20385717 | 0.77 | GGPS1 (0.51) | PLA2G4AFGFR1SRC | |
| SCHEMBL14564402 | 0.74 | NPC1 (0.49) | FGFR1 | |
| SCHEMBL20385716 | 0.74 | FGFR1 (0.49) | PLA2G4AFGFR1TSHRSRC | |
| SCHEMBL20603944 | 0.74 | FGFR1 (0.64) | FGFR1TP53SRC | |
| SCHEMBL21501956 | 0.73 | FGFR1 (0.50) | FGFR1 | |
| SCHEMBL11595848 | 0.73 | MEN1 (0.46) | FGFR1PLA2G4BTP53TSHRPTPN11 | |
| SCHEMBL2361153 | 0.72 | HPGD (0.63) | PLA2G4AFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3348269-B1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFECTIVE VACCINE ADJUVANT | UNIV TSINGHUA (CN) | 2023-11-15 | — | — | EP | disclosed |
| US-20220387584-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | TSINGHUA UNIVERSITY (CN) | 2022-12-08 | — | — | US | disclosed |
| US-11382971-B2 | Mevalonate pathway inhibitor as highly-efficient vaccine adjuvant | TSINGHUA UNIVERSITY (CN) | 2022-07-12 | — | — | US | disclosed |
| US-20190321465-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | TSINGHUA UNIVERSITY (CN) | 2019-10-24 | — | — | US | disclosed |
| EP-3348269-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFECTIVE VACCINE ADJUVANT | Tsinghua University (CN) | 2018-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321465-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | GGPS1, HMGCR, COASY | PLA2G4A 733/4885FGFR1 4021/4885PLA2G4B 726/4885 |
| US-11382971-B2 | Mevalonate pathway inhibitor as highly-efficient vaccine adjuvant | GGPS1, HMGCR, COASY | PLA2G4A 746/4885FGFR1 4019/4885PLA2G4B 738/4885 |
| US-20220387584-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | COASY, GGPS1, HMGCR | PLA2G4A 789/4885FGFR1 4016/4885PLA2G4B 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.